Akira Iwanami
Akira Iwanami has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Wakaho Hayashi
Department of Psychiatry Showa University School of Medicine Tokyo Japan
3 shared publications Katsuma Miyaho
Showa University School of Medicine
2 shared publications- Kenji Sanada
Department of Psychiatry, Showa Medical University Graduate School of Medicine
2 shared publications Nobumasa Kato
Medical Institute of Developmental Disabilities Research, Showa University, 6-11-11 Kitakarasuyama, Setagayaku, Tokyo 157-8577, Japan; Department of Psychiatry, Showa University Karasuyama Hospital, 6-11-11 Kitakarasuyama, Setagayaku, Tokyo 157-8577, Japan
2 shared publications- Shinichiro Nakajima
Department of Neuropsychiatry, Keio University School of Medicine, Japan
2 shared publications - Shunya Kurokawa
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 20 May 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (8) , 3488-3505
Safety and Effectiveness of Guanfacine Hydrochloride Extended-Release in Adult Patients with ADHD in Japan: A Post-Marketing Surveillance Study
This post-marketing surveillance study assessed the safety and effectiveness of guanfacine hydrochloride extended-release (GXR) in adults with attention-deficit/hyperactivity disorder (ADHD) in routine clinical practice in Japan. In this prospective, multicenter study, adults (≥ 18 years) were followed for 1 year after initiating GXR treatment or until treatment discontinuation, whichever occurred first (enrollment: June 2020-March 2022). Hypotension and bradycardia, syncope, blood pressure elevation upon discontinuation, and QT prolongation were key safety concerns for evaluation. Missing data were not imputed; therefore, effectiveness outcomes reflect only the observed data. In total, 961 patients were enrolled across 155 sites; case report forms were collected for 949 patients. Of these, 912 and 784 were included in the safety and effectiveness analyses, respectively. The 12-month GXR continuation rate was 45.2%. Adverse drug reactions (ADRs) reported in ≥ 1% of patients were somnolence (15.02%), dizziness (3.95%), malaise (3.73%), postural dizziness (2.85%), thirst (2.52%), decreased blood pressure (1.86%), hypotension (1.54%), and constipation (1.43%). Seventeen serious ADRs occurred in 13 patients: bradycardia, cerebral ischemia, mental impairment, and syncope (n = 2 each) and decreased blood pressure, delusions, dizziness, postural dizziness, erectile dysfunction, hallucination, psychomotor hyperactivity, somnolence, and suicidal ideation (n = 1 each). Forty-one patients (4.50%) experienced 42 hypotension and bradycardia events (3 were serious). Two patients (0.22%) experienced a syncope event (preferred term: syncope); although both were assessed as non-serious by the investigator, they were classified as serious per the Important Medical Events list. In accordance with the Japanese Risk Management Plan, these two events were also recorded as QT prolongation events (preferred term: syncope). Improvement rates in Clinical Global Impression-Improvement and Patient Global Impression-Improvement scales increased over the 1-year observation period. ADHD-Rating Scale-IV total and subscale scores also improved over time, with significant improvements from baseline observed at all time points (p < 0.0001). No ADRs requiring new safety measures were observed. The effectiveness of GXR in adult ADHD was evident among patients remaining on treatment. UMIN Clinical Trials Registry (identifier: UMIN000040429).
- 20 May 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (8) , 3488-3505
Open AccessSafety and Effectiveness of Guanfacine Hydrochloride Extended-Release in Adult Patients with ADHD in Japan: A Post-Marketing Surveillance Study
This post-marketing surveillance study assessed the safety and effectiveness of guanfacine hydrochloride extended-release (GXR) in adults with attention-deficit/hyperactivity disorder (ADHD) in routine clinical practice in Japan. In this prospective, multicenter study, adults (≥ 18 years) were followed for 1 year after initiating GXR treatment or until treatment discontinuation, whichever occurred first (enrollment: June 2020-March 2022). Hypotension and bradycardia, syncope, blood pressure elevation upon discontinuation, and QT prolongation were key safety concerns for evaluation. Missing data were not imputed; therefore, effectiveness outcomes reflect only the observed data. In total, 961 patients were enrolled across 155 sites; case report forms were collected for 949 patients. Of these, 912 and 784 were included in the safety and effectiveness analyses, respectively. The 12-month GXR continuation rate was 45.2%. Adverse drug reactions (ADRs) reported in ≥ 1% of patients were somnolence (15.02%), dizziness (3.95%), malaise (3.73%), postural dizziness (2.85%), thirst (2.52%), decreased blood pressure (1.86%), hypotension (1.54%), and constipation (1.43%). Seventeen serious ADRs occurred in 13 patients: bradycardia, cerebral ischemia, mental impairment, and syncope (n = 2 each) and decreased blood pressure, delusions, dizziness, postural dizziness, erectile dysfunction, hallucination, psychomotor hyperactivity, somnolence, and suicidal ideation (n = 1 each). Forty-one patients (4.50%) experienced 42 hypotension and bradycardia events (3 were serious). Two patients (0.22%) experienced a syncope event (preferred term: syncope); although both were assessed as non-serious by the investigator, they were classified as serious per the Important Medical Events list. In accordance with the Japanese Risk Management Plan, these two events were also recorded as QT prolongation events (preferred term: syncope). Improvement rates in Clinical Global Impression-Improvement and Patient Global Impression-Improvement scales increased over the 1-year observation period. ADHD-Rating Scale-IV total and subscale scores also improved over time, with significant improvements from baseline observed at all time points (p < 0.0001). No ADRs requiring new safety measures were observed. The effectiveness of GXR in adult ADHD was evident among patients remaining on treatment. UMIN Clinical Trials Registry (identifier: UMIN000040429).
- Open Access
- 23 June 2022
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 1 (2)
Mind wandering in adults with attention deficit hyperactivity disorder: Preliminary evaluation using the Mind Excessively Wandering Scale in a Japanese clinical population
Aim: Mind wandering (MW) has been closely associated with attention deficit hyperactivity disorder (ADHD); however, the field remains understudied in Japan. The present study examined MW in adults with ADHD using the Mind Excessively Wandering Scale (MEWS) in a Japanese clinical population.Methods: Fifty‐two adults with ADHD (mean age, 33.0 years; 33 men), diagnosed per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5) criteria, completed the MEWS, Mind Wandering Questionnaire, Conners' Adult ADHD Rating Scale (CAARS), Autism Spectrum Quotient (AQ), and Japanese Adult Reading Test‐25.Results: The mean MEWS score was 18.8 (standard deviation, 7.6). MEWS scores showed significant correlations with the CAARS Inattention/Memory Problems, Problems with Self‐Concept, DSM‐IV ADHD Symptoms Total, ADHD Index, and AQ scores. Higher MEWS scores were associated with greater ADHD and autism spectrum disorder symptoms in patients with ADHD.Conclusion: Our results not only provide supporting evidence of the presence of excessive MW in adults with ADHD, but also indicate the heterogeneous nature of MW in ADHD.
- 23 June 2022
- Published by Wiley in Psychiatry and Clinical Neurosciences Reports
- Vol. 1 (2)
Open AccessMind wandering in adults with attention deficit hyperactivity disorder: Preliminary evaluation using the Mind Excessively Wandering Scale in a Japanese clinical population
Aim: Mind wandering (MW) has been closely associated with attention deficit hyperactivity disorder (ADHD); however, the field remains understudied in Japan. The present study examined MW in adults with ADHD using the Mind Excessively Wandering Scale (MEWS) in a Japanese clinical population.Methods: Fifty‐two adults with ADHD (mean age, 33.0 years; 33 men), diagnosed per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5) criteria, completed the MEWS, Mind Wandering Questionnaire, Conners' Adult ADHD Rating Scale (CAARS), Autism Spectrum Quotient (AQ), and Japanese Adult Reading Test‐25.Results: The mean MEWS score was 18.8 (standard deviation, 7.6). MEWS scores showed significant correlations with the CAARS Inattention/Memory Problems, Problems with Self‐Concept, DSM‐IV ADHD Symptoms Total, ADHD Index, and AQ scores. Higher MEWS scores were associated with greater ADHD and autism spectrum disorder symptoms in patients with ADHD.Conclusion: Our results not only provide supporting evidence of the presence of excessive MW in adults with ADHD, but also indicate the heterogeneous nature of MW in ADHD.
- 7 January 2022
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 272 (8) , 1481-1494
ASD symptoms in adults with ADHD: a comparative study using ADOS-2
In this study, we examined autism spectrum disorder (ASD) symptoms in adults with attention-deficit hyperactivity disorder (ADHD) in comparison with normal controls using the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2). Sixty-three adults with ADHD (mean age, 35.3 years; 38 men) and 31 controls (mean age, 38.7 years; 17 men) completed Module 4 of the ADOS-2, Autism Spectrum Quotient, Conners’ Adult ADHD Rating Scale, and Wechsler Adult Intelligence Scale, Third Edition. Adults with ADHD were not clinically diagnosed with ASD, and their ADHD diagnosis was based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria. Between-group comparisons on the scoring patterns revealed significant ASD symptoms present in adults with ADHD, which was congruent with our previous study. Further, item level and correlation analyses showed the possibility that ASD symptoms in adult ADHD comprised of two distinct mechanisms, one qualitatively similar to ASD and the other arising from ADHD characteristics, highlighting the complex nature of ADHD-ASD symptom overlaps.
- 7 January 2022
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 272 (8) , 1481-1494
ASD symptoms in adults with ADHD: a comparative study using ADOS-2
In this study, we examined autism spectrum disorder (ASD) symptoms in adults with attention-deficit hyperactivity disorder (ADHD) in comparison with normal controls using the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2). Sixty-three adults with ADHD (mean age, 35.3 years; 38 men) and 31 controls (mean age, 38.7 years; 17 men) completed Module 4 of the ADOS-2, Autism Spectrum Quotient, Conners’ Adult ADHD Rating Scale, and Wechsler Adult Intelligence Scale, Third Edition. Adults with ADHD were not clinically diagnosed with ASD, and their ADHD diagnosis was based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria. Between-group comparisons on the scoring patterns revealed significant ASD symptoms present in adults with ADHD, which was congruent with our previous study. Further, item level and correlation analyses showed the possibility that ASD symptoms in adult ADHD comprised of two distinct mechanisms, one qualitatively similar to ASD and the other arising from ADHD characteristics, highlighting the complex nature of ADHD-ASD symptom overlaps.
- 1 May 2021
- Published by Elsevier in Biological Psychiatry
- Vol. 89 (9) , S341
The Potential Impact of Age on the Gut Microbiota in Patients With Major Depressive Disorders: A Prospective Observational Study
- 1 May 2021
- Published by Elsevier in Biological Psychiatry
- Vol. 89 (9) , S341
The Potential Impact of Age on the Gut Microbiota in Patients With Major Depressive Disorders: A Prospective Observational Study
- 1 May 2021
- Published by Elsevier in Biological Psychiatry
- Vol. 89 (9) , S228-S229
Associations Between Gut Microbiota and Treatment Response in Patients With Major Depressive Disorders Stratified by Dairy Intake: A Prospective Observational Study
- 1 May 2021
- Published by Elsevier in Biological Psychiatry
- Vol. 89 (9) , S228-S229
Associations Between Gut Microbiota and Treatment Response in Patients With Major Depressive Disorders Stratified by Dairy Intake: A Prospective Observational Study
- Open Access
- 9 March 2021
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 41 (2) , 237-241
Similarity of subjective symptoms between autism spectrum disorder and attention‐deficit/hyperactivity disorder in adults: Preliminary findings
Aim The purpose of this study was to examine the symptoms of autism spectrum disorder (ASD) and attention‐deficit/hyperactivity disorder (ADHD) in the adult clinical population using the Autism‐Spectrum Quotient (AQ) and the Adult ADHD Rating Scales self‐report screening version (CAARS‐S:SV). Methods We included 50 adults with ASD and 52 with ADHD diagnosed using the DSM‐5 criteria. Clinical symptoms were evaluated using the AQ and CAARS‐S:SV. Results The AQ score was elevated in the ADHD group and the CAARS scores were increased in the ASD group. Specifically, the total AQ score in adults with ADHD was lower than that in the ASD group, but was higher than that in controls. Similarly, the CAARS scores in adults with ASD were lower than in those with ADHD, but were higher than those in controls. No significant correlations were found between AQ, CAARS Inattention/Memory Problems, and CAARS Hyperactivity/Restlessness scores in both the ASD and ADHD groups. Conclusion While adults with ASD and ADHD exhibited similar clinical symptoms, the absence of AQ‐CAARS correlations suggests the need for examining factors other than the apparent similarity of clinical symptoms of the two disorders.
- 9 March 2021
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 41 (2) , 237-241
Open AccessSimilarity of subjective symptoms between autism spectrum disorder and attention‐deficit/hyperactivity disorder in adults: Preliminary findings
Aim The purpose of this study was to examine the symptoms of autism spectrum disorder (ASD) and attention‐deficit/hyperactivity disorder (ADHD) in the adult clinical population using the Autism‐Spectrum Quotient (AQ) and the Adult ADHD Rating Scales self‐report screening version (CAARS‐S:SV). Methods We included 50 adults with ASD and 52 with ADHD diagnosed using the DSM‐5 criteria. Clinical symptoms were evaluated using the AQ and CAARS‐S:SV. Results The AQ score was elevated in the ADHD group and the CAARS scores were increased in the ASD group. Specifically, the total AQ score in adults with ADHD was lower than that in the ASD group, but was higher than that in controls. Similarly, the CAARS scores in adults with ASD were lower than in those with ADHD, but were higher than those in controls. No significant correlations were found between AQ, CAARS Inattention/Memory Problems, and CAARS Hyperactivity/Restlessness scores in both the ASD and ADHD groups. Conclusion While adults with ASD and ADHD exhibited similar clinical symptoms, the absence of AQ‐CAARS correlations suggests the need for examining factors other than the apparent similarity of clinical symptoms of the two disorders.
- 1 December 2005
- Published by Elsevier in Schizophrenia Research
- Vol. 80 (2-3) , 197-201
Confirmation of a relationship between reduced auditory P300 amplitude and thought disorder in schizophrenia
- 1 December 2005
- Published by Elsevier in Schizophrenia Research
- Vol. 80 (2-3) , 197-201
Confirmation of a relationship between reduced auditory P300 amplitude and thought disorder in schizophrenia